Jillian Ives
Payments from drug & device makers
Across 109 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$307
- Astellas Pharma US Inc$243
- AbbVie$190
- Novo Nordisk$153
- Bayer$149
- Boehringer Ingelheim$127
- plus $662 from 13 others
What the payments were for
- Food & beverage$1,831100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $307 |
| Astellas Pharma US Inc | 15 | $243 |
| AbbVie | 11 | $190 |
| Novo Nordisk | 11 | $153 |
| Bayer | 7 | $149 |
| Boehringer Ingelheim | 7 | $127 |
| Lilly USA, LLC | 6 | $94 |
| Amgen | 5 | $88 |
| Biohaven Pharmaceuticals, Inc. | 5 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $79 |
| Pfizer | 5 | $79 |
| GSK | 4 | $73 |
| Merck | 4 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Seqirus USA Inc | 1 | $13 |
| Biogen | 1 | $13 |
| Abbott | 1 | $12 |
How this compares
$1,831 in reported general payments places this provider in the 75th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 40 | $21,599 |
| EliquisApixaban | 20 | $11,803 |
| JardianceEmpagliflozin | 13 | $7,386 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $6,490 |
| JanuviaSitagliptin Phosphate | 13 | $6,322 |
| VascepaIcosapent Ethyl | 12 | $3,973 |
| Icosapent Ethyl | 11 | $1,391 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $909 |
| Atorvastatin Calcium | 101 | $873 |
| Gabapentin | 35 | $523 |
| Levothyroxine Sodium | 42 | $390 |
| Pantoprazole Sodium | 30 | $382 |
| Omeprazole | 31 | $355 |
| Rosuvastatin Calcium | 40 | $354 |
| Metoprolol Succinate | 14 | $319 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $307 | $21,59940 claims |
| PfizerEliquis | $79 | $11,80320 claims |
| Boehringer IngelheimJardiance | $127 | $7,38613 claims |
| MerckJanuvia | $69 | $6,32213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,395 medical providers in New York.
Other medical in Utica
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
- Hailey BrickmanNew York$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.